Wednesday, 11 November 2026
Strength training with tirzepatide, Doxycycline miscarriage risk signal, Spring-wire guides withdrawn
- 01
Resistance training preserved strength during tirzepatide-associated weight loss
A 40-week trial found resistance training reduced lean-tissue loss and improved strength in people taking tirzepatide for weight management. The study followed 120 men and post-menopausal women aged 50–70 years who had obesity, or overweight with a weight-related health issue but not type 2 diabetes. Participants who trained three times weekly lost an average 22.8 kg, similar to the 22.61 kg lost by those who did not train. The training group lost 25% less lean tissue and improved upper- and lower-body strength by 10%, while strength declined by 10% in the group receiving tirzepatide alone. Researchers said serial DEXA scans showed body composition changed rapidly and argued resistance training should form part of prescribing weight-loss drugs.
via RACGP newsGP
- 02
Doxycycline linked to higher first-trimester miscarriage risk
First-trimester doxycycline exposure was associated with a 40–54% higher risk of pregnancy loss than amoxicillin for respiratory infections, and a 36–39% higher risk than macrolides. US researchers analysed insurance claims from more than 220,000 pregnancies across commercial and Medicaid databases. The higher risk among women with respiratory infections appeared in both databases; among patients with acne, it appeared in the commercial database but not Medicaid. Experts said the active-comparator design strengthened the findings but cautioned that the study did not establish causation or assess full-term pregnancy and foetal outcomes. Doxycycline is widely prescribed for respiratory tract infections and acne and is among Australia’s four most frequently dispensed antibiotics.
via RACGP newsGP
- 03
Hydrophilic spring-wire guides removed over embolism risk
Arrow International has removed products containing hydrophilic spring-wire guide components that may detach and release particles into the bloodstream. The particle shedding poses a risk of embolism. The FDA MedWatch early alert provides limited further detail.
via FDA MedWatch
- 04
Stopping GLP-1 therapy linked to doubled cardiovascular and mortality risk
Stopping GLP-1 receptor agonist treatment was linked to about twice the combined risk of non-fatal heart attack, non-fatal stroke or death from any cause compared with continuing treatment. Researchers examined medical records and GLP-1 treatment use among more than 80,000 people with type 2 diabetes and no history of cardiovascular disease. The incidence rate ratio was 2.01 (95% confidence interval 1.77 to 2.28). The finding is notable because previous research indicated these treatments can reduce cardiovascular events and death, while up to half of patients stop treatment within the first year.
via BMJ
- 05
FDA approves another weekly basal insulin for type 2 diabetes
The US Food and Drug Administration approved another once-weekly basal insulin injection for adults with type 2 diabetes. The source gives limited detail and does not identify the product or provide information about the supporting evidence or approval conditions.
via JAMA
- 06
WHO expands recommended range of contraceptive options
The World Health Organization has released new contraception guidelines that broaden the range of recommended options. WHO described the expanded options as safe and effective. The guidance is relevant to contraception choices, but the source gives limited detail about specific methods or recommendations.
via JAMA
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.